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Management of Parkinson’s disease (PD) is complicated due to its progressive nature, the individual patient heterogeneity, and
the wide range of signs, symptoms, and daily activities that are increasingly affected over its course. *e last 10–15 years have seen
great progress in the identification, evaluation, and management of PD, particularly in the advanced stages. Highly specialized
information can be found in the scientific literature, but updates do not always reach general neurologists in a practical and useful
way, potentially creating gaps in knowledge of PD between them and neurologists subspecialized inmovement disorders, resulting
in several unmet patient needs. However, general neurologists remain instrumental in diagnosis and routine management of PD.
*is review provides updated practical information to identify problems and resolve common issues, particularly when the
advanced stage is suspected. Some tips are provided for efficient communication with the members of a healthcare team
specialized in movement disorders, in order to find support at any stage of the disease in a given patient, and especially for a well-
timed decision on referral.
1. Introduction
Parkinson’s disease (PD) is a disorder with increasing
prevalence worldwide, and the second most common neu-
rodegenerative disorder, surpassed only by Alzheimer’s dis-
ease [1, 2]. Management remains complex over the course of
PD due to its progressive nature, individual patient hetero-
geneity, and wide range of signs, symptoms, and increasingly
affected daily functions. However, the last 10–15 years have
seen great progress in the identification, evaluation, and
management of the disease, particularly in the advanced
stages [3]. *is information does not always reach general
neurologists in a practical and useful way, potentially creating
gaps in knowledge of PD between general neurologists (GNs)
and specialists in movement disorders (MD), resulting in
several unmet patient needs. Nonetheless, GNs remain in-
strumental in diagnosis and routine management in earlier
stages of the disease.*eir ability to identify problems, resolve
common issues, and identify signs of the emerging advanced
stage of PD is paramount for appropriate management [4],
efficient communication with members of the MD team, and
also a well-timed decision on referral.
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*is article therefore aims to provide a practical over-
view of the most up-to-date information from the recent
literature, as well as relevant issues in the management of
PD, in order to support GNs in decision-making and
communication with members of the MD healthcare team.
2. General Characteristics of
Parkinson’s Disease
2.1. Clinical Manifestations and Diagnosis. Clinical mani-
festations of PD may be classified into two groups: motor
symptoms (MS) and nonmotor symptoms (NMS), and they
evolve through three main stages: (1) a preclinical stage, (2) a
premotor stage (with only some NMS present), and (3) a
motor stage with MS. *e GN should suspect PD in people
presenting with resting tremor, rigidity, hypo-/bradykinesia,
and/or postural impairment. Such patients should ideally be
referred untreated to a MD specialist with expertise in the
differential diagnosis of this condition [5], but practice and
availability of MD services in some healthcare settings might
limit this possibility. *erefore, knowledge of the present
diagnostic criteria is necessary.
Due to their relative specificity, only some of the clinical
motor manifestations are taken into consideration as major
criteria for the positive diagnosis of PD. *e UK Brain Bank
criteria are used in many centers for research, but also for
diagnostic purposes (Supplementary table (available here)).
*is already traditional set of criteria has been confirmed by
large neuropathological studies [6]. More recent diagnostic
criteria are those of the International Parkinson and
Movement Disorder Society (MDS, 2015). In the MDS set of
criteria, the main criterion for diagnosis of PD is the
presence of parkinsonism, defined as bradykinesia, in
combination with either rigidity or resting tremor, or both
[7]. All of these are motor manifestations. After confirma-
tion of parkinsonism and evaluation of “absolute exclusion
criteria” (symptoms not present in PD), “red flags”
(symptoms atypical for PD), and also “supportive criteria”
(symptoms typically or often present in PD), the specialist
may diagnose either clinically established PD or clinically
probable PD, as shown in Figure 1 [7]. *e MDS criteria
enable the diagnosis of PD at an earlier stage, take into
account some early complex nonmotor aspects of the dis-
ease, and exclude posture and balance impairment as a
major sign of the disease, as these are more related to the
advanced stage.
Key messages for diagnosis of Parkinson’s disease are as
follows:
(i) *ere are two different diagnostic criteria for the
clinical diagnosis of Parkinson’s disease.
(ii) *e first and most important feature of Parkinson’s
disease is bradykinesia: tremor without bradyki-
nesia is not enough for the diagnosis of parkin-
sonism or Parkinson’s disease.
(iii) Patients correctly diagnosed with Parkinson’s dis-
ease should have a clear effect of their anti-
parkinsonian medications if the dose is sufficient.
However, some motor symptoms such as tremor
can result from a combination of dopaminergic and
nondopaminergic brain lesions, which may con-
tribute to variable response to levodopa across
patients [8].
2.2. Heterogeneity of Symptoms in PDas a Progressive Disease.
Typical MS include hypomimia, dysarthria, dysphagia, de-
creased arm swing, shuffling gait, festinations, freezing,
difficulty rising from a chair, difficulties with turning in bed,
cutting food, feeding and hygiene, micrographia, presence of
inexhaustible glabellar reflex, blepharospasm or other dys-
tonia, and camptocormia [9]. Some represent components
of the natural history of the disease, while others are related
to dopaminergic therapy. Additionally, NMS are more
numerous than MS; the most frequent are presented in
Table 1 [10–13]. Some NMS may occur as early as the
premotor stage of PD (e.g., hyposmia, REM-sleep behavior
disorder, depression, constipation, excessive daytime
sleepiness, fatigue, pain, and erectile dysfunction), while
others (dementia, hallucinations, etc.) usually occur later on
in the course of the disease [13]. With all this in mind, there
are several instruments that can aid the MD specialist in
identification and assessment of severity of symptoms and
disability level (Section 3).
2.3. Classifications of PD. All MS and NMS do not appear
together in every patient. In fact, studies on larger cohorts
reveal the existence of NMS+MS clusters in different
clinical subtypes of PD [14–20]. Although there is no general
consensus regarding PD subtypes, different variables taken
into account in classifications (MS, NMS, genetic criteria,
drug-induced complications, etc.) may point to some
common conclusions. However, it is important to emphasize
that there is no clear demarcation between phenotypic
subtypes, as most of their clinical features overlap and only
the dominance of some clusters of symptoms defines a
certain subtype [21].
It is believed that the so-called “precision medicine”
concept [22] will eventually guide the physician towards the
best possible personalized care for an individual patient and
his/her personal needs and requirements [21].
2.4. Complications Related to Pharmacological Treatment.
*e available pharmacological treatments for PD, based
largely on dopaminergic drugs, are symptomatic only. *ey
allow PD patients to improve their functional status and
health-related quality of life (HRQoL), mainly during the
early years after clinical onset of the disease. Unfortunately,
presently available therapies do not halt disease progression.
Biologic disease-related dysfunctions and the pharmaco-
logical properties of drugs interact and often induce drug-
related complications such as motor and nonmotor fluc-
tuations, dyskinesia, impulse control disorder (ICD), do-
paminergic dysregulation syndrome (DDS), punding,
dopamine-agonist withdrawal syndrome (DAWS), and
levodopa withdrawal syndrome. Some complications can be
ameliorated or delayed with optimization of oral therapy
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(Section 4.1) for several years until the advanced stage is
reached.
Levodopa-related clinical fluctuations have various
clinical presentations, and very often, the nonmotor fluc-
tuations precede and/or accompany the motor ones [23].
Among the motor fluctuations, the earliest to occur is the
“wearing-off” (end of dose deterioration), which is defined as
a progressive shortening of the period between dose intakes
of levodopa [10] due to a progressive shortening of the “on”
time duration and an earlier than previously expected “off”
occurrence. Other fluctuations include [10] suboptimal
clinical response, delayed-on and no-on response (altered
Screen for parkinsonism
Bradykinesia
AND
Resting tremor OR Rigidity
Not clinical PD
(or possibly early stages)
Screen for absolute exclusion criteria Not clinical PD
Screen for red flags
No red flags 
+
≥2 supportive criteria
≤2 red flags 
+
Equal number of supportive criteria (balanced)
Screen for supportive criteria
Present
Absent
Absent
>2 red flags
Present
≤2 red flags 
Clinically established PD Clinically probable PD
Absolute exclusion criteria
(1) Unequivocal cerebellar abnormalities.
(2) Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades.
(3) Probable behavioral variant frontotemporal dementia or primary progressive aphasia, within the first 5 y of disease.
(4) Parkinsonian features restricted to the lower limbs for >3 years.
(5) Possible drug-induced parkinsonism according to treatment history
(6) No response to high-dose levodopa despite at least moderate severity of disease.
(7) Unequivocal cortical sensory loss, clear limb ideomotor apraxia, or progressive aphasia.
(8) Normal functional neuroimaging of the presynaptic dopaminergic system.
(9) Documentation of an alternative condition known to produce parkinsonism and plausibly connected to symptoms.
Red flags
(1) Rapid progression of gait impairment requiring regular use of wheelchair within 5 y of onset.
(2) Absence of progression of motor symptoms or signs over ≥5 y unless stability related to treatment.
(3) Early bulbar dysfunction: severe dysphonia or dysarthria or severe dysphagia within first 5 y.
(4) Inspiratory respiratory dysfunction: inspiratory stridor or frequent inspiratory sighs.
(5) Severe autonomic failure within 5 y of disease onset. 
(a) Orthostatic hypotension
(b) Severe urinary retention or urinary incontinence not attributable to other condition. 
(6) Recurrent (>1/y) falls because of impaired balance within 3 y of onset.
(7) Disproportionate anterocollis (dystonic) or contractures of hand or feet within the first 10 y.
(8) Absence of any of the common nonmotor features of disease despite 5 y disease duration. Including: sleep 
dysfunction, autonomic dysfunction, hyposmia, or psychiatric dysfunction.
(9) Otherwise-unexplained pyramidal tract signs, excluding mild reflex asymmetry and isolated extensor plantar 
response.
(10) Bilateral symmetric parkinsonism. 
Supportive criteria
(1) Clear and dramatic beneficial response to dopaminergic therapy. 
(a) Marked improvement with dose increases or marked worsening with dose decreases (>30% in UPDRS III with 
change in treatment or clearly-documented history of marked changes). 
(b) Marked on/off fluctuations, and predictable end-of-dose wearing off.
(2) Levodopa-induced dyskinesia.
(3) Resting tremor of a limb
(4) Either olfactory loss or cardiac sympathetic denervation.
Figure 1: Summary diagram of Parkinson’s disease diagnosis based on the diagnostic criteria of the movement disorder society [7].
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pharmacokinetics due to impaired motility of the upper
gastrointestinal tract, mainly delayed emptying of the
stomach), unpredictable “off” episodes, and freezing (motor
blocks). However, it should be borne in mind that some
fluctuations are not necessarily drug-related; for example,
“on” freezing may be unresponsive to dopaminergic med-
ication and may be present due to extensive lesions of the
nondopaminergic structures of the brain.
*e main clinical types of motor complications include
(1) peak-dose dyskinesia, dominated by choreic movements
and less frequently dystonic features during the “on” period,
usually associated with high dopaminergic medication blood
levels, (2) “off” dystonia, usually associated with low do-
paminergic medication blood levels and “off” periods and
that maymanifest by painful foot inversion; off dystonia may
develop as “early-morning dystonia” that manifests on
awakening before the first dose of levodopa), daytime and
nocturnal dystonia; and, (3) diphasic (biphasic) dyskinesia
that usually manifests as choreic and/or dystonic move-
ments at the beginning and the end of the “on” period.
Dyskinesia represents an abnormal hyperkinetic movement
that is different to those specific to the natural evolution of
PD. It is related to the effects of the dopaminergic therapy
(mainly levodopa) in interaction with the neuroplasticity
mechanisms. Dyskinesia may impair daily activities signif-
icantly (troublesome dyskinesia) or nonsignificantly (non-
troublesome dyskinesia) [24]. *is clinical distinction of
severity is important for treatment decisions.
ICDs include pathological gambling, compulsive buying,
hypersexual disorders, or binge eating, and ICD-related
disorders such as DDS, punding, compulsive hoarding, or
aimless wandering [25]. *ese disorders have been associ-
ated to various drugs, including levodopa, amantadine, and
rasagiline. Intake of dopamine agonists has been reported as
a major risk factor for developing ICDs [25, 26], but it
remains unclear whether long-acting agonists and nonoral
formulations may reduce the risk [27], nor association with
DA dose, treatment duration, or peak dose has been
established [25, 26]. At any rate, prevalence of ICDs
increases over time in PD. It has been described that early
onset of PD and presence of motor complications may be
associated to higher risk of ICDs [25, 26].
It should be borne in mind that not all clinical mani-
festations of PD are dopaminergic in nature and that
nondopaminergic symptoms (such as autonomic dysfunc-
tion, sleep disorders, pain syndromes, mood disturbances,
and dementia) are largely unresponsive to currently avail-
able therapeutic possibilities. *ese nondopaminergic
symptoms often dominate in advanced stages of the disease
and cause more severe disability and impairment of quality
of life (QoL) than dopaminergic symptoms [28].
2.5. Progressing toAdvancedDisease. As PD is clinically very
heterogenous and progressive in nature, it is not an easy task
to define the concept of advanced PD. Various efforts in the
form of systematic analyses, expert consensuses from na-
tional steering committees in Europe [24], and Delphi
studies with specialized MD panelists [29, 30] have been
made to propose criteria. Advanced PD is generally reached
when patients develop characteristic complications associ-
ated with long-term levodopa treatment, uncontrolled with
optimized conventional therapies [29]. *e common feature
in all proposals to characterize advanced PD is the impact of
disease manifestations on disability and QoL. However the
concept is “still controversial and is variably applied to
patients with long disease duration or with motor fluctua-
tions and severe or moderate dyskinesia, with impairment of
gait, equilibrium, cognition or neuropsychiatric symptoms”
[29]. *e authors of a recently published consensus [29]
found the development of severe motor fluctuations with
disabling “off” periods to be the most important factor; both
MS and NMS, either related to the evolution of the disease or
to the long-term levodopa therapy, are considered essential
for the diagnosis of advanced PD. Accordingly, there is
growing awareness of nonmotor aspects of PD as indicators
of the advancing course. NMS, unfortunately, are not
properly reflected in the usual scale-based assessments,
Table 1: Most frequently described nonmotor symptoms of Parkinson’s disease due to natural history of the disease or related to therapy
[10–13].
Domain Symptoms
Autonomic
Blood pressure variations with orthostatic hypotension, tachycardia, urinary disturbances (such
as urgency, frequency), nocturia, sexual dysfunction, hypersexuality (likely to be drug-induced),
paroxysmal sweating, seborrhea, xerostomia (“dry eyes”), facial hyperemia, mydriasis, pallor
Gastrointestinal (partly related to
dysautonomia) Drooling of saliva, ageusia, dysphagia, constipation, fecal incontinence, eructation, meteorism
Sleep REM sleep behavior disorder (RBD), excessive daytime sleepiness, vivid dreams, insomnia,periodic limb movements (PLM), restless legs syndrome (RLS)
Neuropsychiatric
Cognitive impairment (including mild cognitive impairment and dementia), depression,
anhedonia, apathy, anxiety, panic attacks, delirium, hallucinations, illusions, delusions, impulse
control disorder (ICD), dopaminergic dysregulation syndrome, dopamine agonist withdrawal
syndrome (DAWS)
Sensory Pain, olfactory disturbance, blurred vision, visual discrimination deficits (also related toneurocognitive impairment)
Miscellaneous Fatigue, diplopia, weight loss or weight gain (often drug- and evolution-related)
Note: this list is not exhaustive. Abbreviations are given for terms that are often used in the abbreviated form.
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which are largely focused onMS [31]. Practical cues on when
advanced disease might be suspected are described in Sec-
tion 4.3.
Key messages for follow-up in Parkinson’s disease are as
follows:
(i) Patient diaries may be used to evaluate ON time
without dyskinesia, ON time with dyskinesia and
OFF time once motor fluctuations appear. However,
appropriate training is required for reliable keeping
of the diaries (Supplementary file).
(ii) Nonmotor symptoms and potential side effects of
medications are often not reported by the patients.
Both aspects should be actively screened by the
treating neurologist.
3. Evaluation of Clinical Manifestations
Numerous rating scales have been developed to assess
multidimensional aspects of PD more reliably. A detailed
description of diagnostic tools is beyond the scope of this
article, but GNs should be familiar with updated informa-
tion on the various instruments used in the MD specialist
clinic and their interpretation. *e most relevant tools
evaluating MS and NMS, dyskinesia, sleep quality, and
HRQoL are summarized and described in Table 2, along with
the most important grading schemes. Knowledge of com-
mon scales and their interpretation may be of use for the GN
when communicating with an MD specialist and discussing
results. When interpreting results, the minimal clinically
important difference (MCID) threshold values may also be
considered. MCID is the smallest change in an outcome
measure that a patient or clinician would identify as im-
portant, therefore representing the threshold above which
the outcome is experienced as relevant by the patient. *is
parameter may be more useful to the MD specialist than
statistical significance, since some changes may be statisti-
cally significant in the research literature but reflect no
clinical relevance.
4. Management according to the Disease Stage
Several studies support the early introduction of anti-
parkinsonian treatment as soon as the diagnosis is confirmed
[52]. Oral levodopa, the initial gold-standard therapy for PD,
is still the most effective and widely used therapeutic option
in the treatment of this neurodegenerative disorder. How-
ever, its use eventually results in the development of motor
fluctuations and levodopa-induced dyskinesia (LID) [53].
Nearly 40% of PD patients develop LID after 4 to 6 years of
levodopa treatment [54].
*erefore, particularly in younger patients in whom
motor complications typically occur earlier and are more
severe, pharmacological treatment should be started with
MAO B inhibitors or dopamine agonists, adding levodopa
later on as soon as needed. One of the mechanisms by which
motor fluctuations and LID occur is the intermittent,
nonphysiological pulsatile manner in which oral levodopa
stimulates dopaminergic receptors [55, 56]. When
symptoms cannot be optimally alleviated with conventional
oral medications, it is time to apply the strategies of con-
tinuous dopaminergic administration by introducing the so-
called “advanced therapies” or “device-aided treatments”
(Section 4.2). However, before reaching this advanced stage,
the appropriate use of available oral treatments might help
optimize conventional pharmacotherapy in patients (Sec-
tion 4.1), and some nonpharmacological approaches should
be attempted in PD management (Section 4.3).
4.1. Optimization of Conventional Oral Medication. In the
early stages of PD, symptoms can generally be alleviated or
abolished by MAO-B inhibitors, dopamine agonists, or with
low-dose levodopa taken three or four times daily (“hon-
eymoon period”). Initial choice likely has no long term effect
[57], so levodopa treatment in younger patients who need
more powerful motor improvement should not be avoided.
In fact, most of the patients who started with dopamine
agonists will require levodopa treatment after several years.
In addition, as previously mentioned, patients with early
onset of PD are more prone to develop ICD (more often
caused by dopamine agonists). In summary, treatment
should be considered carefully and individually based on
personality and psychiatric and physical comorbidities.
As the disease progresses, successful management will
increasingly require addition of more antiparkinsonian
medications, as well as increased dosages and frequency of
drug intake. A detailed history should be taken from the
patient and his/her caregiver to identify problems, such as
underdosing, new motor and nonmotor signs, motor and
nonmotor fluctuations, and motor and nonmotor side ef-
fects of medication [58]. While proper identification of these
issues is crucial for further management, there is no de-
finitive expert consensus on the actual medication picture of
a candidate for switching to advanced PD therapies; that is,
there is no agreement on the combination of drugs and
dosages that would help define a patient no longer well
controlled with regular oral medication. Nevertheless, there
are several good practice points and generally accepted
interventions for troublesome issues, such as morning “off,”
wearing “off,” delayed and failed “on,” peak-of-dose dys-
kinesia, biphasic dyskinesia, troublesome night-time “off”
periods, and others (Table 3), requiring assessment by an
MD specialist earlier in the disease course.
For practical purposes, patients should be using ≥5 ef-
fective doses of levodopa daily before considering transition
to advanced therapies [30]. If “off” periods persist, adding
MAO-B inhibitors and/or COMT-inhibitors should be
considered [59]. If possible, dopamine agonists should be
used at the maximum tolerated dose (not inducing side-
effects) and amantadine should be considered for severe
dyskinesia [61]. Motor fluctuations and dyskinesias are not
necessarily associated with the duration of levodopa
therapy, but rather with longer disease duration and higher
levodopa daily dose [62]. If the effect of individual levodopa
doses is shorter than 3 hours, it is unlikely that further
shortening of intervals will lead to sufficient control of
symptoms [63].
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Table 2: Instruments for general assessment, health-related quality of life assessment, and complications of Parkinson’s disease.
Assessment tool Abbrev. Measures Grading severity MCID Quick tips
Hoehn and Yahr
Scale [32] HYS General assessment
Mild: HYS 1 and 2
Moderate: HYS 3
Severe: HYS 4 and 5
Besides the
original version, a
modified version
(mHYS) is also
available
Unified
Parkinson’s
Disease Rating
Scale [33]
UPDRS
General assessment,
4 subscales:
Part I: mentation,
behavior and mood
Part II: activities of
daily living
Part III: motor
examination
Part IV: treatment
complications
Part II: 0.7 (early PD) [34], 2
(HYS 1&2) [35], 3 points (HYS
2.5–3) [35]
Part III: 2.4 (early PD) [34], 5
(HYS 1–3) [35], 3.5 (advanced)
[36]
In most cases, the
total score is
calculated as the
sum of parts
I + II + III
Movement
Disorders
Society-
Sponsored
Unified
Parkinson’s
Disease Rating
Scale [37]
MDS-
UPDRS
General assessment,
4 subscales:
Part I: non-motor
experiences of daily
living
Part II: motor
experiences of daily
living
Part III: motor
examination
Part IV: motor
complications
Score [38]: Score change:
Solves several
ambiguities of
UPDRS; subscales
should be
interpreted
separately
Mild Moderate Severe Improvement Worsening
Part
I ≤10 11–21 ≥22 PartI[39] −2.64 2.45
Part
II ≤12 13–29 ≥30 PartII[39] −3.05 2.51
Part
III ≤32 33–58 ≥59 PartIII[40] −3.25 4.63
Parkinson’s
Disease
Questionnaire
(39 items) [41]
PDQ-39
Disease-specific
health-related
quality of life
39 items grouped
into 8 domains
making up a
summary index
Score change [42]:
Improvement −4.72 points,
Worsening 4.22 points
One of the most
relevant
instruments
Parkinson’s
Disease
Questionnaire (8
items) [43]
PDQ-8
Disease-specific
health-related
quality of life. 8
questions making
up a summary index
Improvement −5.94 [42] (range:
−4.6, −10) [36, 44]
Worsening 4.91 points [42]
*is is the “short”
version of PDQ-
39
Nonmotor
Symptoms Scale
[45]
NMSS
Measures nine
domains:
Cardiovascular,
sleep/fatigue, mood/
cognition,
perception
problems, attention
& memory,
gastrointestinal-
urinary, sexual
function, and
miscellaneous
Absent or mild: 0–20 points
Moderate: 21–40 points
Severe: 41–70 points
Very severe: ≥ 71 points [46]
*ere is also a
screening
instrument
(NMSQ); NMSS
assesses severity
and frequency
Parkinson’s
Disease Sleep
Scale 2nd version
[47]
PDSS-2
Overall sleep
quality;
3 subscales on
motor problems at
night, PD problems
at night and
disturbed sleep
Absent or minimal: 0–10
points
Mild-moderate: 11–20 points
Severe: ≥20 points [48] Improvement −3.44 pointsWorsening 2.07 points [49]
PDSS-2 is an
improved version
of the original
PDSS
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Presently, there is no consensual agreement among MD
specialists as to the defining clinical features of advanced
disease [64] and when advanced therapies should be in-
troduced. *e GN should be familiar with signs and features
that lead to suspicion of advanced PD and contact an MD
specialist in a timely manner, so an appropriate assessment
and complementary interventions can be carried out. *e
disease duration and the emergence of motor [65] and
nonmotor [66] complications are crucial for the diagnosis of
advanced PD. Antonini et al. [30] published a series of
indicators for transition to advanced PD achieved with a
Delphi approach that may provide good orientation
(Table 4).
Key messages for treatment of Parkinson’s disease
(initial stages) are as follows:
(i) When choosing medication, individual approach is
required based on symptoms and preference.
(ii) Start low and go slow until reaching good clinical
benefit
(iii) Medications with a more continuous stimulation
profile, such as dopamine agonists or MAO-B in-
hibitors, are preferred in initial stages if appropriate
for the clinical profile of the patient
(iv) Levodopa should not be avoided at all costs, even in
initial stages. Consider levodopa if other medica-
tions are not indicated or not effective.
4.2. Advanced :erapies for Advanced Stages. In patients in
whom conventional oral pharmacotherapy has been
exhausted and cannot be optimized, three main device-
assisted therapies should be considered, all of them based on
the concept of CDS: (1) continuous subcutaneous infusion of
apomorphine; (2) intra-intestinal infusion of levodopa-
carbidopa gel (LCIG); and (3) deep-brain stimulation (DBS).
*e optimal timing for initiating these advanced therapies to
improve QoL and prevent complications is critical and
requires that patients and caregivers be informed early about
the evolution to later stages of the disease with their com-
plications [21]. As the decision to initiate any of these
therapies should be made by a MD specialist and a multi-
disciplinary team [69], the role of the GN in timely referral is
critical for adequate patient management. Currently, there
are no large studies comparing the procedures [70], and the
choice between therapies is based upon many consider-
ations, as shown in Table 4.
Apomorphine, a D1 and D2 dopamine receptor agonist,
has rapid onset of action and is used in earlier stages as
rescue injections during “off” periods. In advanced PD, it is
delivered as a continuous subcutaneous infusion by means
of a portable pump. It has shown effectiveness in treatingMS
and some NMS in advanced stages of the disease [71, 72].
LCIG is delivered directly to the proximal jejunum via a
percutaneous gastrojejunostomy (PEG-J) tube connected to
a portable infusion pump [73]. *is therapy is used to avoid
erratic gastric emptying and to improve intestinal absorp-
tion. LCIG is an effective treatment for reducing motor
fluctuations, improving “on” time without dyskinesia and
improving HRQoL in advanced PD [74].
Deep brain stimulation (DBS) is a functional neuro-
surgical procedure that can be used to treat motor fluctu-
ations, dyskinesia, and tremor [75]. It has also been shown to
improve HRQoL [76]. However, levodopa-unresponsive
symptoms in advanced PD (e.g., gait instability, psychiatric
disorders, cognitive impairment, dysarthria, and autonomic
dysfunction) are unlikely to improve with DBS [77].
*e key to the success of any advanced therapy is ap-
propriate patient selection, including the patient’s prefer-
ence whenever possible. A multidisciplinary team should be
involved in patient and treatment selection, and its partic-
ipation is also imperative in the follow-up [69].
Key messages for treatment of Parkinson’s disease
(advanced stages) are as follows:
(i) If good ON period is shorter than 3 hours, further
adjustments of oral medications will most likely fail,
and advanced treatments should be considered.
(ii) Indication of advanced treatment options should
not be delayed if standardmedications fail to control
sufficiently motor fluctuations.
(iii) Do not delay referral or contact with a team spe-
cialized in movement disorders if advanced disease
is suspected.
4.3. Nonpharmacological Interventions across All Stages.
*e main goal of any management should be to maintain
acceptable levels of functioning and independence. In
Table 2: Continued.
Assessment tool Abbrev. Measures Grading severity MCID Quick tips
Unified
Dyskinesia
Rating Scale [50]
UDysRS
Overall assessment
of dyskinesia:
Part I: historical On-
Dyskinesia
Part II: historical
Off-Dystonia
Part III: objective
Impairment
Part IV: objective
disability
Part III:
Improvement 2.32 points
Worsening 2.76 points [51]
UDysRS is the
most
comprehensive
dyskinesia scale
MCID, minimal clinically important difference; PD, Parkinson’s disease.
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advanced PD, this can be achieved with a careful combi-
nation of drugs and supportive nonpharmacological therapy
[78] in the context of collaboration between the GN, the MD
specialist, and the multidisciplinary team. Supportive
nonpharmacological management in advanced PD patients
should include physical rehabilitation, psychological sup-
port, occupational therapy, speech, language and swallowing
therapy, and nutrition [78, 79], among other possible in-
terventions (Table 5). Balance and gait have been shown to
improve with physical therapy and exercise, thus reducing
the risk of falling [86, 87]. Physical activity has beneficial
effects in PD, and forms that have shown benefit include
aerobic exercise including dancing and treadmill training,
resistance training, and traditional activities such as Tai Chi
and yoga [88]. High intensity training may also improve the
motor symptoms and limitations [89]. Speech therapy has
been successfully used to improve hypophonic and
hypokinetic speech and related functions, such as swal-
lowing problems associated with PD [82, 90]. Integration of
medical and nonmedical treatments is most efficiently
planned by members of a multidisciplinary team, usually
established as part of tertiary MD centers.
5. Multidisciplinary and Team Approach across
All Stages
When a broad range of MS and NMS is set within the
framework of individual requirements and priorities of each
patient, the need for close and personalized care becomes
obvious. *is is best achieved by a multidisciplinary team.
Such a team is often part of a tertiary center for movement
disorders. From a practical point of view, the GN should find
out whether there is a multidisciplinary team in the local
hospital or conveniently located elsewhere for the patient.
Table 3: Pragmatic optimization of oral medications for selected issues related to Parkinson’s disease management.
A. Most relevant motor and non-motor symptoms that may lead to suspicion of inadequately controlled Parkinson’s disease (ranked by
level of importance) [58]
Motor Non-motor
(1) troublesome level of motor fluctuations
(2) two hours of the day with “off” symptoms
(3) At least 1
hour of the day with troublesome dyskinesia
(4) Presence of motor complications
(5) daily multiple oral levodopa doses)
(1a) Troublesome hallucinations/psychosis
(1b) Non-motor symptom fluctuations
(2a) Impulse control disorder
(2b) Troublesome level of nighttime sleep disturbances
(3a) Troublesome level of depression
(3b) Troublesome level of daytime sleepiness
B. Pragmatic approach: questions for the patient If answer is NO: potentialproblem Potential solutions
Are your symptoms sufficiently controlled?
Insufficient effect–the
patient might be
underdosed
(i) Increase dose of dopamine agonist
(ii) Increase individual levodopa doses
When you wake up in the morning, is your mobility
acceptable? If not, how long does it take for your
medication to start working?
Troublesome morning “off”
time
(i) Prescribe morning levodopa for immediately
after waking up
(ii) Increase dopamine agonist dose (use more
in the evening)
(iii) If morning levodopa dose is less effective
compared to other doses–increase this
individual dose
When your medication starts working, does the effect last
until the next dose? If not, how long do you experience
symptoms?
Wearing off (motor or non-
motor symptoms)
(i) Increase dopamine agonist dose
(ii) Prescribe more frequent doses of levodopa
(iii) Add a COMT inhibitor (e.g. entacapone,
tolcapone) [59, 60]
(iv) Add an MAO-B inhibitor (e.g. selegiline,
rasagiline [59, 60]
Does the effect of some of your doses take long to start or
do you completely fail to experience its effects?
Delayed “on”
Failed “on”
(i) Indicate the use of levodopa always at least
30–45 minutes before or after meals (not with
food)
(ii) Prescribe prokinetics (e.g. domperidone)
(iii) Exclude Helicobacter pylori and/or SIBO
syndrome
Do you have excessive involuntary movements when your
medication is working? Dyskinesia
(i) Prescribe levodopa in lower doses and more
frequently
(ii) Add amantadine [61]
Is your mobility during the night acceptable? Troublesome nighttime“off”
(i) Prescribe immediate-release levodopa for
nighttime wake-ups
(ii) Increase dopamine agonist (to use more in
the evening)
COMT, catechol-O-methyl transferase; MAO-B, monoamine oxidase B; SIBO, small intestine bacterial overgrowth.
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Contact with a reference team may be of use as early as the
initial stages of the disease to provide advice or support to
resolve common issues. However, members of a multi-
disciplinary team will play an essential role, particularly in
advanced stages. *e GN should contact the team coor-
dinator (often a specialized PD nurse) to help as a pivotal
point of communication with other members of the team.
Cooperation between the GN, caregiver, patient, and the
multidisciplinary team is a multichannel and bidirectional
pathway and, from time to time, it may be useful for the
GN (and/or patient and caregiver) to attend a team
meeting.
At these meetings, the GN will establish contact with the
core members of the team, particularly the neurologist-MD
specialist, PD nurse, and—when and if needed—also with a
psychologist, social worker, physiotherapist, occupational
therapist, and speech therapist. *ese professionals are
specially trained to provide advice, education, and support,
which should be tailored to the needs of the individual
patient and can be obtained much faster when in direct
communication with experts. If needed, other professionals
such as a sex therapist, dietitian, psychiatrist, gastroenter-
ologist, and neurosurgeon might be involved, usually
through the team meetings. Table 5 lists the activities and
Table 4: Characteristics of patients with Parkinson’s disease who might be eligible for advanced device-aided therapies [29, 30, 58].
Characteristics of patients as proposed by expert-opinion studies
Motor Non-motor Function
(i) Troublesome level of motor fluctuations
[29, 30, 58]
(ii) At least 1 hour of the day with
troublesome dyskinesia [30, 58]
(iii) At least 2 hours of the day with “off”
time [29, 30, 58]
(iv) Off-period postural instability [29, 30]
(v) Dystonia with pain [30]
(vi) Freezing of gait during “off” time [30]
(vii) Daily multiple oral levodopa doses
[58]
(i) Non-motor symptom fluctuations
[58]
(ii) Impulse control disorder [58]
Troublesome level of nighttime sleep
disturbances [30, 58]
(iii) Severe dysphagia and recurrent
falls [29]
(iv) Troublesome level of daytime
sleepiness [58]
(v) Troublesome level of anxiety [58]
(i) Needing help with activities of daily living at least
some of the time (limited) [29, 30]
Proposed profiles according to clinical characteristics [30]
Characteristics Apomorphine Deep brain stimulation(DBS)
Levodopa carbidopa
Intestinal gel (LCIG)
Younger age (<70 years) Probably good candidate [58] Probably goodcandidate [58] Probably good candidate [58]
Older age (>70 years) Probably good candidate [67, 68] Possible candidate[67, 68] Probably good candidate[67, 68]
Good levodopa response Probably good candidate [58] Probably goodcandidate [58]
Definitely good candidate
[58]
Levodopa-resistant tremor Not a candidate [58, 67] Definitely goodcandidate [58, 67] Not a candidate [58, 67]
Troublesome dyskinesia Possible candidate Probably goodcandidate [58] Probably good candidate [58]
Good cognitive function Probably good candidate [58] Probably goodcandidate [58] Probably good candidate [58]
Nighttime sleep disturbances Possible candidate [58] Possible candidate [58] Possible candidate [58]
Pain Possible candidate [58] Possible candidate [58] Possible candidate [58]
Impulse control disorder Not a candidate [58, 67, 68] Possible candidate[58, 67, 68]
Possible candidate
[58, 67, 68]
Depression Possible candidate [58, 68] Not a candidate[58, 68] Possible candidate [58, 68]
Apathy Possible candidate [58] Not a candidate [58] Possible candidate [58]
Anxiety Not a candidate [58] Possible candidate [58] Possible candidate [58]
Mild dementia Possible candidate [67, 68] Not a candidate[67, 68] Possible candidate [67, 68]
Multimorbidity Possible candidate [67]/Not acandidate [68] Not a candidate [67]
Possible candidate [67]/Not
a candidate [68]
Lack of social support/caregiver Not a candidate [67] Possible candidate [67] Not a candidate [67]
Excessive daytime sleepiness Not a candidate [68] Possible candidate [68] Possible candidate [68]
Dysphagia Probably good candidate [68] Not a candidate [68] Probably good candidate [68]
In all studies cited, the recommendations are based on clinical experience and expert opinion in the absence of robust comparative evidence. If “possible” or
“probably good” candidate is described, check warnings for use in the label that should be taken into consideration.
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kind of support the usual multidisciplinary team members
may provide.
6. Conclusion
*e progressive and multifocal nature of PD adds com-
plexity to the management of this disease, with important
and increasing prevalence in the aging population. Recent
advances in the knowledge of PD provide growing insight
not only into mechanisms of the disorder but also into
greater understanding of patients’ needs and the use of
relevant tools to improve their QoL. General neurologists
attending PD patients at any stage may benefit from a
practical update of this knowledge. *ere is a lot that GNs
can do for their PD patients in earlier stages, as well as in
advanced stages, particularly when in good and timely
communication with a multidisciplinary team, whether for
advice, support interventions, or referral when necessary.
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